Pharma & FDA
Drug approvals, recalls, regulation, biotech pipelines, and the commercial side of medicine.
Why this topic matters right now
This topic is gaining attention due to recent developments, public interest, and its broader impact across related areas. Stay informed with our comprehensive coverage and analysis of the latest trends and implications.
Latest coverage
FDA clarifies how biosimilar makers can change manufacturing postapproval
A new FDA Q&A aims to spell out what happens when biosimilar manufacturers change how products are made after approval—and what evidence regulators expect.
FDA Highlights New Drug Approvals for Rare Diseases
Recent FDA communications detail new drug approvals for rare diseases, outlining options for patients with limited existing treatments.
FDA Uses PREA Non‑Compliance Letters to Press Drugmakers on Pediatric Data
Regulators are formally warning drug sponsors that miss pediatric study deadlines under federal law, a move that can affect how medicines are labeled for children.
FDA Creates Quantitative Medicine Hub Inside Key Drug Review Center
The FDA’s drug center has launched a Quantitative Medicine Center of Excellence to coordinate how data-driven methods shape drug development and review.
FDA’s CDER Details Streamlined Nonclinical Studies and New Test Methods
FDA’s drug center is outlining when streamlined nonclinical studies and new testing methods are acceptable, with patient safety kept at the center.
FDA’s Chief Medical Office Publishes Three-Year Guidance Agenda
The FDA’s Office of the Chief Medical Officer has released a public agenda of guidance documents planned through 2027, inviting review and input.
Texas Compounding Pharmacy Recalls Glutathione Injection Nationwide
Optimal Balance Pharmacy in Houston has issued a voluntary nationwide recall of a lot of compounded glutathione injectable vials, reaching down to patients.
How the FDA’s Competitive Generic Therapy Pathway Shapes Drug Access
The FDA’s Competitive Generic Therapy approvals list offers a narrow but telling view into how regulators are trying to push more generics into markets with little or no competition.
FDA Sets Updated Intake Limits for Nitrosamine Drug Impurities
FDA’s drug center has updated its recommended limits for nitrosamine drug substance-related impurities, shaping how manufacturers manage cancer-linked risks.
How FDA Patent Certifications Shape the Path for Generic Drugs
FDA patent certifications and suitability petitions quietly determine when and how generics can reach patients. Here is what they do and why timing matters.
What FDA’s Generic Drug Facility Lists Signal — and What They Don’t Yet
The FDA’s Generic Drug Facilities, Sites and Organization Lists are live. Whether they become a formal, near-term reference point is less certain.
Showing 12 of 43 articles
FDA Probes Rare Neurologic Complications Tied to Common Anesthetic
U.S. regulators are examining reports of catastrophic brain injury and death after sevoflurane anesthesia in patients with suspected genetic risk.
BsUFA IV and FY 2028: What We Actually Know Right Now
With thin public evidence and a long lead time, the odds of BsUFA IV’s FY 2028 plans being locked in next week look low—and hard to quantify.
FDA Posts Frequently Requested Foreign Drug Plant Inspection Records
FDA is proactively releasing inspection and compliance records for foreign drug manufacturers, aiming to speed access to information often sought through FOIA.
BsUFA IV and FY 2028: What Is Known—and What Is Not
With BsUFA IV now law, attention turns to how far its framework really extends toward FY 2028—and what that means for biosimilar oversight.
FDA Outlines Generic Drug User Fee Amendments Framework
FDA details how the Generic Drug User Fee Amendments work, including fee types and payment procedures for companies that make generic medicines.
How the FDA’s Competitive Generic Therapy Pathway Shapes Drug Access
The FDA’s Competitive Generic Therapy pathway targets drugs with little or no competition. Here’s how it works, who benefits, and what remains uncertain.
Why Individual Case Safety Reports Sit at the Heart of Drug Safety
A closer look at the FDA’s Individual Case Safety Reports and how this data standard shapes the way potential drug side effects are tracked.
FDA Flags Dough-To-Go for Food Safety Control Failures
A recent FDA action against Dough-To-Go, Inc. spotlights gaps in preventive food safety controls and what they mean for regulators and consumers.
How ICH Q10 Is Reframing the Pharmaceutical Quality System
A closer look at the ICH Q10 Pharmaceutical Quality System guideline and how regulators say it can help drug makers manage risk and consistency.
FDA’s ‘Information by Drug Class’ Effort: What It Is and What Comes Next
The FDA is organizing safety and availability information by drug class. Here is what that means for patients, prescribers and industry in the near term.
FDA Flags CGMP Failures at Alchymars ICM SM Over API Quality
U.S. regulators cite Alchymars ICM SM Private Limited for CGMP violations tied to active pharmaceutical ingredient quality and potential adulteration.
FDA Highlights First Generic Drug Approvals for 2025
The FDA’s drug center has published its early list of 2025 first generic approvals, a key marker for when lower-cost versions of brand medicines can reach patients.
FDA Withdrawn Oncology Accelerated Approvals: What the Move Signals
The FDA has listed certain cancer accelerated approvals as withdrawn. Here is what that means now, and why formal confirmation in the next week is uncertain.
FDA Clears Enhertu for Two Uses in Early HER2-Positive Breast Cancer
Regulators grant dual approvals for fam-trastuzumab deruxtecan-nxki in adults with early-stage HER2-positive breast cancer, expanding treatment options.
FDA Clears Two New Uses for T-DXd in Early HER2-Positive Breast Cancer
The FDA has approved two indications for trastuzumab deruxtecan in early HER2-positive breast cancer. Here is what that means and what remains uncertain.
What the FDA’s Drugs@FDA Data Files Reveal—and What Comes Next
The FDA’s Drugs@FDA Data Files open a structured window into approved drugs. Here’s what the new ZIP, data definitions, and ERD actually change.
What FDA’s 503A Bulk Drug Rules Mean for Compounded Medicines
FDA tightens which bulk substances can be used in 503A compounding, shaping what customized medicines pharmacies may legally prepare for patients.
FDA Converts Select Cancer Drugs From Accelerated to Traditional Approval
The FDA has confirmed clinical benefit for several cancer drugs first cleared under its accelerated approval pathway, converting them to traditional approvals.
What the FDA’s Drugs@FDA Data Files Reveal—and What They Don’t Yet Settle
The FDA’s Drugs@FDA Data Files offer a structured view of drug approvals. Here is what is now available, and why firm conclusions should wait for more evidence.
What the FDA’s Expanded Selumetinib Approval Means for Young NF1 Patients
The FDA has extended selumetinib’s use to NF1 patients as young as 1. Here is what is confirmed, what is still thinly documented, and why timing matters.
FDA’s Withdrawn Accelerated Cancer Approvals: What Is Really Known Now
An FDA list shows certain accelerated oncology approvals have been withdrawn. Evidence is thin on next steps, leaving key questions about timing and impact.
How FDA’s CDER SBIA Guides Small Drug Firms Through Regulation
FDA’s CDER Small Business and Industry Assistance program helps small drug companies navigate complex human drug regulations and FDA resources.
FDA Moves Ahead With Quality Metrics Program for Drug Manufacturing
The FDA is advancing a quality metrics reporting program for drug makers, aiming to reduce shortages and encourage more reliable manufacturing.
FDA’s SBIA Learn Expands Online Help for Small Drug Developers
FDA’s CDER SBIA Learn platform packages regulatory guidance into short videos and tools designed to make drug development rules easier for small firms.
FDA Opens GDUFA IV Information Hub for Fiscal Year 2028 Planning
The FDA has created a dedicated page for information on GDUFA IV, covering fiscal year 2028, signaling early steps toward the next generic drug user fee cycle.
FDA Flags Sexual Enhancement and Energy Products With Hidden Drugs
Agency warns some over-the-counter sexual enhancement and energy products contain undisclosed prescription drugs or other hidden ingredients.
What the iPLEDGE REMS Means for Patients Using High‑Risk Acne Drugs
The FDA’s iPLEDGE Risk Evaluation and Mitigation Strategy aims to reduce the danger of severe birth defects from certain acne medicines.
How Firm Is the iPLEDGE REMS? Assessing the Near-Term Outlook
The FDA’s iPLEDGE REMS is designed to curb embryo‑fetal risk. What is actually known about its status—and how likely is formal confirmation in the coming week?
Torrent Pharmaceuticals Cited by FDA for Adulterated Finished Drugs
U.S. regulators have flagged Torrent Pharmaceuticals Limited for CGMP violations tied to adulterated finished medicines, raising quality and oversight questions.
How Every Cure’s Drug Search Aims to Rewrite Rare Disease Treatment
A small nonprofit is trying to match existing drugs to overlooked rare diseases, challenging how new treatments are usually found and funded.
FDA clears rare disease drug as Washington scrutiny on patents intensifies
A new FDA approval for a rare genetic disorder lands as senators press patent officials and lawmakers push to cap insulin costs.